ACTA1 and neoplasm: In addition, Ent treatment reduced the volumes of the CK19+ tumor cells, as well as the α-SMA+ activated stromal fibroblasts and the SR+ stromal collagen content (Fig. 7f, Supplementary Fig. 8a), supporting the bicompartmental targeting capacities of Ent to reduce tumor progression and stromal activation.